{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:24:17Z","timestamp":1794335057391,"version":"4.9.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Tropica"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.actatropica.2026.108175","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T23:03:47Z","timestamp":1780787027000},"page":"108175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy of delayed tafenoquine administration for radical cure of Plasmodium vivax Malaria: A systematic review"],"prefix":"10.1016","volume":"280","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2354-329X","authenticated-orcid":false,"given":"Timothy N.","family":"DeVita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9890-2664","authenticated-orcid":false,"given":"Jimee","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6769-7322","authenticated-orcid":false,"given":"Julie R.","family":"Gutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4109-3464","authenticated-orcid":false,"given":"Alison D.","family":"Ridpath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2631-2216","authenticated-orcid":false,"given":"Seymour","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8984-0895","authenticated-orcid":false,"given":"Michelle A.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.actatropica.2026.108175_bib0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002299","article-title":"Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of plasmodium vivax infection in Ethiopia: a randomized controlled trial","volume":"14","author":"Abreha","year":"2017","journal-title":"PLoS Med."},{"issue":"2","key":"10.1016\/j.actatropica.2026.108175_bib0002","first-page":"301","article-title":"Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine","volume":"46","author":"Alving","year":"1955","journal-title":"J. Lab. Clin. Med."},{"issue":"10195","key":"10.1016\/j.actatropica.2026.108175_bib0003","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0140-6736(19)31096-7","article-title":"Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study","volume":"394","author":"Battle","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.actatropica.2026.108175_bib0005","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/14740338.2021.1859476","article-title":"Tafenoquine: a toxicity overview","volume":"20","author":"Chu","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"issue":"10","key":"10.1016\/j.actatropica.2026.108175_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.35719","article-title":"Public health response to the first locally acquired malaria outbreaks in the US in 20 years","volume":"8","author":"DeVita","year":"2025","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.actatropica.2026.108175_bib0007","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/1475-2875-10-212","article-title":"Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta)","volume":"10","author":"Dow","year":"2011","journal-title":"Malar. J."},{"issue":"1","key":"10.1016\/j.actatropica.2026.108175_bib0008","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12936-020-03184-x","article-title":"Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review","volume":"19","author":"Duparc","year":"2020","journal-title":"Malar. J."},{"issue":"11","key":"10.1016\/j.actatropica.2026.108175_bib0009","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.trstmh.2008.04.024","article-title":"The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific","volume":"102","author":"Elmes","year":"2008","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"4","key":"10.1016\/j.actatropica.2026.108175_bib0010","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/BF00542151","article-title":"The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects","volume":"26","author":"Frisk-Holmberg","year":"1984","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.actatropica.2026.108175_bib0011","unstructured":"GlaxoSmithKline (2018). Kozenis (tafenoquine) approved by the Australian TGA for the radical cure of P. vivax malaria."},{"key":"10.1016\/j.actatropica.2026.108175_bib0012","series-title":"KRINTAFEL (tafenoquine) tablets, for Oral Use","year":"2020"},{"issue":"2","key":"10.1016\/j.actatropica.2026.108175_bib0013","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4269\/ajtmh.1955.4.221","article-title":"The treatment of malaria with hydroxychloroquine","volume":"4","author":"Hoekenga","year":"1955","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"3","key":"10.1016\/j.actatropica.2026.108175_bib0014","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1710775","article-title":"Single-dose tafenoquine to prevent relapse of plasmodium vivax malaria","volume":"380","author":"Lacerda","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"9922","key":"10.1016\/j.actatropica.2026.108175_bib0015","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(13)62568-4","article-title":"Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study","volume":"383","author":"Llanos-Cuentas","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.actatropica.2026.108175_bib0016","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa1802537","article-title":"Tafenoquine versus Primaquine to prevent relapse of plasmodium vivax Malaria","volume":"380","author":"Llanos-Cuentas","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.actatropica.2026.108175_bib0017","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12936-023-04725-w","article-title":"Effect of adherence to primaquine on the risk of plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis","volume":"22","author":"Mehdipour","year":"2023","journal-title":"Malar. J."},{"issue":"6","key":"10.1016\/j.actatropica.2026.108175_bib0018","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bcp.12160","article-title":"Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects","volume":"76","author":"Miller","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.actatropica.2026.108175_bib0019","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1473-3099(21)00358-3","article-title":"Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial","volume":"22","author":"Poespoprodjo","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.actatropica.2026.108175_bib0020","article-title":"Antirelapse efficacy of various primaquine regimens for Plasmodium vivax","volume":"2014","author":"Rajgor","year":"2014","journal-title":"Malar. Res. Treat."},{"issue":"9","key":"10.1016\/j.actatropica.2026.108175_bib0021","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nbt0918-785a","article-title":"FDA approves first single-dose antimalarial","volume":"36","author":"Ratner","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.actatropica.2026.108175_bib0022","first-page":"13","article-title":"Comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis'","author":"Sharma","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.actatropica.2026.108175_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.2019-9-1","article-title":"Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues","volume":"8","author":"Shukla","year":"2019","journal-title":"Drug. Context."},{"key":"10.1016\/j.actatropica.2026.108175_bib0024","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.actatropica.2026.108175_bib0025","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S1473-3099(23)00213-X","article-title":"Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study","volume":"23","author":"Sutanto","year":"2023","journal-title":"Lancet Infect. Dis."},{"issue":"5","key":"10.1016\/j.actatropica.2026.108175_bib0026","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2165\/00003088-199325050-00005","article-title":"Clinical pharmacokinetics of slow-acting antirheumatic drugs","volume":"25","author":"Tett","year":"1993","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.actatropica.2026.108175_bib0027","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12936-018-2378-2","article-title":"Primaquine 30 mg\/day versus 15 mg\/day during 14 days for the prevention of Plasmodium vivax relapses in adults in French Guiana: a historical comparison","volume":"17","author":"Valdes","year":"2018","journal-title":"Malar. J."},{"issue":"4","key":"10.1016\/j.actatropica.2026.108175_bib0028","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1086\/315034","article-title":"Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of plasmodium vivax malaria in Thailand","volume":"180","author":"Walsh","year":"1999","journal-title":"J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.actatropica.2026.108175_bib0029","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1086\/424508","article-title":"Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse","volume":"39","author":"Walsh","year":"2004","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.actatropica.2026.108175_bib0030","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jac\/dkg319","article-title":"Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant plasmodium falciparum, in agreement with its physicochemical properties","volume":"52","author":"Warhurst","year":"2003","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.actatropica.2026.108175_bib0031","first-page":"13","article-title":"Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis'","author":"Watson","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.actatropica.2026.108175_bib0032","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.83433","article-title":"The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis","volume":"11","author":"Watson","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.actatropica.2026.108175_bib0033","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/B978-0-12-397900-1.00002-5","article-title":"Relapse","volume":"80","author":"White","year":"2012","journal-title":"Adv. Parasitol."},{"key":"10.1016\/j.actatropica.2026.108175_bib0034","series-title":"Prequalification of Medical Products","article-title":"First tafenoquine products prequalified","year":"2024"},{"key":"10.1016\/j.actatropica.2026.108175_bib0035","series-title":"WHO Guidelines For Malaria","year":"2024"},{"key":"10.1016\/j.actatropica.2026.108175_bib0036","series-title":"World Malaria Report 2025: Addressing the Threat of Antimalarial Drug Resistance","year":"2025"}],"container-title":["Acta Tropica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001706X26002081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001706X26002081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:39:31Z","timestamp":1794332371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001706X26002081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":35,"alternative-id":["S0001706X26002081"],"URL":"https:\/\/doi.org\/10.1016\/j.actatropica.2026.108175","relation":{},"ISSN":["0001-706X"],"issn-type":[{"value":"0001-706X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of delayed tafenoquine administration for radical cure of Plasmodium vivax Malaria: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Acta Tropica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actatropica.2026.108175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108175"}}